

Sheffield biomedical imaging expert seconded to leading UK skin cancer imaging firm

(Orpington, UK) March 10, 2011 - Dr Stephen Matcher, Senior Lecturer in Biomedical Engineering at the Department of Materials Science and Engineering at the University of Sheffield, has been seconded to Orpington, UK-based start-up Michelson Diagnostics Ltd for 6 months, to provide the company with the benefits of his expertise in Optical Coherence Tomography (OCT), an advanced technique for skin imaging used in their products.

The secondment is enabled by a grant from the Royal Academy of Engineering (RAE) Industrial Secondment Scheme. This scheme is intended to help companies gain access to highly qualified academic expertise and to build links with universities, and at the same time for academics to gain experience of working in industry, so that they can impart the fruits of this experience to their students through teaching, and to help them focus their own research programmes on the most relevant topics.

During his secondment, Dr Matcher will help develop advanced image processing algorithms for use in Michelson's 'VivoSight' laser scanners for imaging skin cancers and other skin conditions. The project started in February 2011.

Dr Matcher joined the University of Sheffield as Senior Lecturer in 2006. His principal research interests are in the development and application of novel biophotonic tools to aid characterisation of biological tissues, especially for use in medicine and tissue engineering. He has worked in OCT research for more than 10 years. Dr Matcher is currently supported by EPSRC to develop polarization-sensitive OCT and to develop advanced light sources for OCT imaging.

"I am very pleased that the RAE is supporting my secondment to Michelson Diagnostics, a world leader in OCT imaging" said Dr Matcher, "and I hope that my skills and expertise will be of practical benefit to the company".

Jon Holmes, CEO of Michelson Diagnostics, commented "Dr Matcher is already providing invaluable insights and research. His secondment enables us to develop and test new capabilities with huge future potential, without disrupting our near-term product development programme."

Image



Dr Steve Matcher,
Senior Lecturer in Biomedical
Engineering, University of
Sheffield, has been seconded
to Michelson Diagnostics.

Media Enquiries

Adrienne.Harris@md-ltd.co.uk

Notes to editors

Dr Stephen J Matcher's details and research interests are at:
<http://www.shef.ac.uk/materials/staff/matcher.html>

Details of the Royal Academy of Engineering Industrial Secondment Scheme are available at:
<http://www.raeng.org.uk/research/univ/secondment/default.htm>

About Michelson Diagnostics

Michelson Diagnostics was founded in 2006; it is privately owned and based in Kent, U.K. The company develops imaging products using a technology called Multi-Beam Optical Coherence Tomography. The technology provides real time images of up to 2 mm into tissue with a resolution of better than 10 microns. The company's VivoSight OCT scanner has CE and 510(k) clearance for use to aid clinical judgments in the field of dermatology including non-melanoma skin cancer assessment and guiding skin cancer surgery.

Further information about Michelson Diagnostics can be found on the Internet at <http://www.md-ltd.co.uk/> or by emailing enquiries@md-ltd.co.uk .

For clinical use in the US FDA 510(k) K093520 applies:

- The VivoSight Topical OCT system is indicated for use in the two-dimensional, cross-sectional, real-time imaging of external tissues of the human body. This indicated use allows imaging of tissue microstructure, including skin, to aid trained and competent clinicians in their assessment of a patient's clinical conditions.
- US Federal law restricts this device to sale by or on the order of a physician.

The Michelson Diagnostics logo and the VivoSight name are the trademarks of Michelson Diagnostics Ltd and are registered in the UK, the US & throughout the European Union

Octopus Investments Ltd (www.octopusinvestments.com) is an investor in Michelson Diagnostics.

Octopus Investments, founded in 2000, is a leading investment specialist, offering a range of core and satellite investment solutions. It has grown its funds under management by almost 100% per annum since inception, and now employs over 170 people to manage almost £2 billion in funds under management.

Octopus has won a number of awards for its products and customer service. It has twice been voted one of the Best 100 SMEs to work for by the Sunday Times, and is one of only two fund management companies to be AAA rated by IFAs for customer service.